title: Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Kudo
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Mizuho
authors.initials: M
authors.lastname: Tsushima
authors.forename: Makoto
authors.initials: M
authors.lastname: Mizuta
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Matsuo
authors.forename: Toshiro
authors.initials: T
authors.lastname: Yonei
authors.forename: Toshio
authors.initials: T
authors.lastname: Sato
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018450:Disease Progression; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride